HASBROUCK HEIGHTS, N.J., March 27, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today that the Company's FDA Cleared NicAlert™ product continues to achieve widespread acceptance around the world as an important tool in tobacco-related research studies and programs in a broad range of healthcare areas. Researchers in the UK, Canada, Holland, Switzerland, Australia, Brazil, India, and Hong Kong as well as those in major research institutions across the U.S. are employing NicAlert™ in their studies as reported in many new and recent peer-reviewed publications. NicAlert™ testing has been used in such areas as:
NicAlert™ received clearance from the U.S. Food and Drug Administration to measure tobacco use and exposure and achieved certification for sale in the European Union with the CE Mark. The saliva-based version of NicAlert™ has achieved certification with the CE Mark, permitting its sale in the European Union. TobacAlert™ which employs the same technology is available for non-medical use as an over-the counter product in the U.S. for detecting second-hand smoke exposure using urine samples. "NicAlert™ provides a quick, simple, and inexpensive means for companies, universities, hospitals and research institutions to verify smoking status and obtain a semi-quantitative measure of a person's level of tobacco use or exposure," said Brian Doyle, Nymox's Director of Business Development. "NicAlert™ testing does not require special training and can deliver accurate results on site in a matter of minutes. Now researchers and staff can screen potential subjects in a matter of minutes rather than having to wait hours or days for the results to come back from the lab. This generates efficiency and saves time and expense for all concerned."
- studies of the effectiveness of tobacco cessation programs (e.g. Addictive Behaviors March 2013; 38 1792–1795; Journal of Perinatology (2012) 32, 374–380; J Am Board Fam Med. 2013 Jan-Feb;26(1):61-70);
- the extent of exposure to secondhand smoke by children of smokers (Thorax 2013 online publication February 10, 2013);
- the accuracy of NicAlert™ to verify smoking status in patients about to undergo surgery (Nicotine Tob Res. 2013 Mar 20. [Epub ahead of print]); and
- the use of saliva NicAlert™ for confirmation of smoking status by dentists treating periodontal disease (J Indian Soc Periodontol. 2012 Oct-Dec;16(4): 508–512).
NicAlert™ employs Nymox's proprietary technology to measure levels of cotinine, a metabolite of nicotine widely accepted to determine tobacco product use and second-hand smoke exposure. The product requires no instruments for its use and provides an on-site visual read-out of the level of tobacco use or exposure within minutes.Independent studies have confirmed the accuracy and effectiveness of Nymox's testing technology. Recently published independent studies confirming the accuracy of NicAlert™ to verify smoking status as compared to much more complex and expensive laboratory testing include Nicotine Tob Res. 2013 Mar 20. [Epub ahead of print] and Drug Alcohol Depend. 2011; 119: 130–133. An earlier study by researchers at the Centers for Disease Control and Prevention (CDC) found that NicAlert™ measurements correlated well with the far more complex laboratory testing (liquid chromatography-mass spectrometry) used in the CDC laboratory (Journal of Analytical Toxicology 2005; 29: 814-818). Other studies have also found the technology employed in NicAlert™ to be accurate, rapid and cost-effective (Cancer Epidemiology, Biomarkers & Prevention 2007; 16:1858-62; Cancer Epidemiology, Biomarkers & Prevention 2002; 11:1123-1125; Nicotine & Tobacco Research 2002; 4:305-9). NicAlert™ comes in two formats: NicAlert™ Saliva which uses saliva samples for verifying smoking status and measuring high levels of consumption and NicAlert™ Urine which uses urine samples and can provide data not only on smoking status but also second-hand smoke exposure and levels of tobacco product use. More information about Nymox is available at www.nymox.com, email: email@example.com, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: For Further Information Contact: Brian Doyle Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com